Modalis and Exegenesis Bio expanded their collaboration to push MDL-201 toward the clinic for Duchenne muscular dystrophy. The program uses Modalis’ epigenome editing technology to sustainably and selectively activate utrophin in muscle tissue—an approach aimed at improving dystrophic outcomes beyond direct exon-skipping. Funding also moved in Fragile X syndrome as Connecta Therapeutics secured $3.5 million to accelerate clinical development of CTH120 for adult males with Fragile X. The financing is positioned to complete a Phase IIa trial and support next-stage work tied to the FRAXCURE project funded by the EIC Accelerator program.